Dr. Greder supports patent prosecution in the areas of biotechnology and biological engineering. In addition, Dr. Greder provides assistance with due diligence, freedom-to-operate, and patent landscape review.
Prior to joining the firm, Dr. Greder earned his Ph.D. in cell and molecular biology at the University of Oxford. As the Oxford-Sir David Weatherall Scholar, Dr. Greder investigated the gene regulatory interactions governing the birth of hematopoietic stem cells during development at single cell resolution. Dr. Greder has also spent time doing target identification, target validation, and in vitro disease modeling in the pharmaceutical industry and helping to run a core facility in academia.
Dr. Greder has technical expertise in the following areas:
- Gene editing (e.g., CRISPR/Cas9 used for knockouts, knockins, CRISPRa, and CRISPRi)
- Functional genomics (e.g., whole-genome screening with pooled and arrayed CRISPR/Cas9 libraries)
- Genomic and transcriptomic profiling (e.g., RNA-seq, ChIP-seq, and ATAC-seq)
- Bioinformatics (e.g., NGS data analysis)
- Single cell biology (e.g., sc-qRT-PCR, sc-RNA-seq, single cell multi-omics (DNA/RNA from same cell))
- Synthetic biology (e.g., designing genetic circuits and synthetic signaling pathways)
- Molecular biology (e.g., molecular cloning)
- In vitro disease modelling (e.g., differentiation of human iPSC to various lineages)
- Gene therapy (e.g., lentiviral, AAV, and adenoviral mediated-delivery)